PHARMACOSMOS A/S

Egen beskrivelse på virk.dk

Pharmaceuticals Pharmacosmos’ pharmaceutical products are marketed worldwide through subsidiaries in Norway, Sweden, the UK, Germany, the USA, and Canada, as well as through partners in countries such as Poland, Brazil, South Africa, South Korea, and Japan. The company’s pharmaceutical activities focus on the prevention and treatment of iron deficiency and iron deficiency anemia - one of the most widespread global health conditions, affecting more than one billion people. Pharmacosmos develops intravenous iron therapies for patients who cannot tolerate or do not adequately absorb oral iron. Monofer®/Monoferric® (ferric derisomaltose) continues to be a key growth driver within the Pharmaceuticals business area. Its differentiated product profile allows for high-dose administration in a short time, enabling most patients to meet their full iron need in a single visit. This remains a strong competitive advantage. In 2024/25, Pharmacosmos significantly expanded its presence in oncology care through the acquisition of G1 Therapeutics Inc., a U.S.-based commercial-stage biopharmaceutical company. This strategic move brought the FDA approved product Cosela® (trilaciclib) into our portfolio. Cosela® is the first and only myeloprotective therapy for patients with extensive-stage small cell lung cancer. Cosela®’s mechanism of action is designed to selectively protect the bone-marrow from the effects of chemotherapy, thereby significantly reducing the risk of patients experiencing severe reductions in white blood cell, red blood cell, and platelet concentration. Pharmacosmos is working to make Cosela® available to more patients in the USA and to secure regulatory approvals internationally. Carbohydrates Pharmacosmos is a world leading manufacturer of dextrans, dextran derivatives and customized dextrans for pharmaceutical use. With strong expertise in carbohydrate chemistry, Pharmacosmos specializes in polysaccharide production and fractionation. As a result, the company markets dextran used in various therapeutic applications, including separation processes, lyophilization, virus and protein stabilization, organ preservation, treatment of shock conditions, and cryopreservation of cells. Animal Health In the veterinary sector, Pharmacosmos is a leading manufacturer of injectable iron for the prevention and treatment of anemia. Its brand, Uniferon®, is one of the world’s leading injectable iron preparations. The majority of piglets worldwide receive injectable iron shortly after birth. Pharmacosmos’ veterinary iron products are marketed in over 60 countries. Company's primary activities Pharmacosmos A/S (hereafter “Pharmacosmos”) is a fully integrated pharmaceutical company headquartered in Holbæk, Denmark, with subsidiaries in Norway, Sweden, the UK, Germany, the USA, and Canada. Pharmacosmos is a specialized company. Building on our foundational expertise in carbohydrate chemistry and cell cycle biology, we develop innovative treatments for unmet patient needs, with a focus on iron metabolism and blood-related disorders. The company operates within three business areas: Pharmaceuticals, Carbohydrates, and Animal Health. Pharmacosmos is GMP-certified by regulatory authorities in Denmark, the EU, the USA, Canada, Switzerland, Australia, China, and Japan. The company continuously invests in clinical research and development.